PROK Stock Analysis: Buy, Sell, or Hold?
PROK - ProKidney Corp. Class A Ordinary Shares
$1.80
-0.04 (-2.17%)
âŧ
5d:
-6.25%
30d:
+21.62%
90d:
+8.43%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When PROK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PROK is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PROK is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PROK is currently trading at $1.80, which is considered slightly high relative to its 30-day fair value range of $1.48 to $1.87.
Technical Outlook: Technically, PROK is in a uptrend. The price is currently testing key support at $1.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PROK scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.25 (+247.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PROK is in a uptrend. The price is currently testing key support at $1.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PROK scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.25 (+247.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.48 -
$1.87
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 247.2% below Wall St target ($6.25)
- WARNING: Composite score 34/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.48 -
$1.87
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.75
Resistance Level
$2.09
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.07
Wall Street Target
$6.25
(+247.2%)
Revenue Growth (YoY)
-32.1%
Share & Embed Analysis
Last updated: September 13, 2026 7:46 AM ET
Data refreshes hourly during market hours. Next update: 8:46 AM
Data refreshes hourly during market hours. Next update: 8:46 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PROK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 50 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
